利拉鲁肽对血糖增高的代谢综合征疗效分析

目的探讨利拉鲁肽治疗血糖增高的代谢综合征的临床疗效。方法选取2012年1月至2014年1月我院收治的血糖增高的代谢综合征患者192例,按照随机数字表法分为观察组和对照组各96例,观察组和对照组均给予同样的饮食和运动方案,观察组给予利拉鲁肽治疗,对照组给予二甲双胍治疗,两组的疗程均为3个月。检测两组患者的空腹胰岛素、体质指数、血糖、血脂、血清脂联素等生化指标,计算稳态模型胰岛素抵抗指数（HOMA-IR）和总体胰岛素敏感指数（WBISI）并进行对比。结果治疗前,观察组和对照组患者在体质指数（BMI）、腰围（WC）、收缩压（SBP）、舒张压（DBP）、空腹血糖（FPG）、餐后2 h血糖（2 h PG）、空腹胰岛素（FINS）、甘油三脂（TG）、胆固醇（TC）、高密度脂蛋白-胆固醇（HDL-C）、低密度脂蛋白-胆固醇（LDL-C）、HOMA-IR、WBISI和血清脂联素方面比较差异均无统计学意义（P〉0.05）;治疗后,观察组和对照组患者以上各指标均较治疗前明显改善,观察组改善明显优于对照组,差异具有统计学意义（P〈0.05）。结论利拉鲁肽治疗血糖增高的代谢综合征临床疗效显著,其机制可能与增强胰岛素敏感性、减轻胰岛素抵抗、降低体重及调节血清脂联素水平有关。

Curative effect of Liraglutide in the treatment of hyperglycemia metabolic syndrome

Objective To investigate the curative effect of Liraglutide in the treatment of hyperglycemia metabolic syndrome. Methods Totally 192 patients with hyperglycemia metabolic syndrome admitted in our hospital from Jan. 2012 to Jan. 2014 were selected and divided into the observation group and control group（n=96） according to random number table method. Same diet and exercise plan were given to the observation group and control group.Then the observation group was given Liraglutide treatment, while the control group was given metformin treatment.The treatment course was both 3 months. The fasting insulin, body mass index, blood glucose, blood lipid, serum adiponectin and other biochemical indicators were detected and compared. The steady-state model of insulin resistance index（HOMA-IR） and whole body insulin sensitivity index（WBISI） were calculated. Results Before treatment, there were no statistically significant differences（P〉0.05） between the groups＇ body mass index（BMI）, waist circumference（WC）, systolic blood pressure（SBP）, diastolic blood pressure（DBP）, fasting plasma glucose（FPG）, 2 h postprandial blood glucose（2 h PG）, fasting insulin（FINS）, triglycerides（TG）, cholesterol（TC）, high-density lipoprotein cholesterol（HDL-C）, low density lipoprotein cholesterol（LDL-C）, HOMA-IR, WBISI and serum adiponectin; After treatment,the above indexes of the observation group and control group were both obviously improved, and the improved situation of observation group was significantly better than that of the control group. The difference was statistically significant（P〈0.05）. Conclusion The curative effect of Liraglutide in treatment of hyperglycemia metabolic syndrome is significant. Enhancing insulin sensitivity, reducing insulin resistance and regulating serum adiponectin level may be the mechanism.